Publications
Found 3 results
Filters: Author is M.A. Siddiqi [Clear All Filters]
“Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population”, vol. 10, pp. 3038-3045, 2011.
, Abate-Shen C and Shen MM (2000). Molecular genetics of prostate cancer. Genes Dev. 14: 2410-2434.
http://dx.doi.org/10.1101/gad.819500
Adler V, Yin Z, Fuchs SY, Benezra M, et al. (1999). Regulation of JNK signaling by GSTp. EMBO J. 18: 1321-1334.
http://dx.doi.org/10.1093/emboj/18.5.1321
PMid:10064598 PMCid:1171222
Antognelli C, Mearini L, Talesa VN, Giannantoni A, et al. (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63: 240-251.
http://dx.doi.org/10.1002/pros.20184
PMid:15538743
Autrup JL, Thomassen LH, Olsen JH, Wolf H, et al. (1999). Glutathione S-transferases as risk factors in prostate cancer. Eur. J. Cancer Prev. 8: 525-532.
http://dx.doi.org/10.1097/00008469-199912000-00008
PMid:10643942
Bostwick DG, Burke HB, Djakiew D, Euling S, et al. (2004). Human prostate cancer risk factors. Cancer 101: 2371-2490.
http://dx.doi.org/10.1002/cncr.20408
PMid:15495199
Choi JY, Neuhouser ML, Barnett M, Hudson M, et al. (2007). Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol. Biomarkers Prev. 16: 1115-1120.
http://dx.doi.org/10.1158/1055-9965.EPI-07-0040
Debes JD, Yokomizo A, McDonnell SK, Hebbring SJ, et al. (2004). Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer. Cancer Genet. Cytogenet. 155: 82-86.
http://dx.doi.org/10.1016/j.cancergencyto.2004.03.015
PMid:15527908
Fleshner NE and Klotz LH (1998). Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev. 17: 325-330.
http://dx.doi.org/10.1023/A:1006118628183
PMid:10453275
Garcia-Saez I, Parraga A, Phillips MF, Mantle TJ, et al. (1994). Molecular structure at 1.8 Åof mouse liver class pi glutathione S-transferase complexed with S-(p-nitrobenzyl)glutathione and other inhibitors. J. Mol. Biol. 237: 298- 314.
http://dx.doi.org/10.1006/jmbi.1994.1232
PMid:8145243
Harries LW, Stubbins MJ, Forman D, Howard GC, et al. (1997). Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18: 641-644.
http://dx.doi.org/10.1093/carcin/18.4.641
PMid:9111193
Hayes JD and Strange RC (2000). Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61: 154-166.
http://dx.doi.org/10.1159/000028396
PMid:10971201
Henderson CJ, McLaren AW, Moffat GJ, Bacon EJ, et al. (1998). π-class glutathione S-transferase: regulation and function. Chem. Biol. Interact. 111-112: 69-82.
http://dx.doi.org/10.1016/S0009-2797(97)00176-2
Hsing AW and Chokkalingam AP (2006). Prostate cancer epidemiology. Front. Biosci. 11: 1388-1413.
http://dx.doi.org/10.2741/1891
PMid:16368524
Jeronimo C, Varzim G, Henrique R, Oliveira J, et al. (2002). I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 11: 445-450.
PMid:12010858
Kelada SN, Kardia SL, Walker AH, Wein AJ, et al. (2000). The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol. Biomarkers Prev. 9: 1329-1334.
PMid:11142418
Konwar R, Manchanda PK, Chaudhary P, Nayak VL, et al. (2010). Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population. Asian Pac. J. Cancer Prev. 11: 1067-1072.
PMid:21133626
Kote-Jarai Z, Easton D, Edwards SM, Jefferies S, et al. (2001). Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 11: 325-330.
http://dx.doi.org/10.1097/00008571-200106000-00007
PMid:11434510
McCarty KM, Santella RM, Steck SE, Cleveland RJ, et al. (2009). PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk. Environ. Health Perspect. 117: 552-558.
PMid:19440493 PMCid:2679598
Mir O, Alexandre J, Tran A, Durand JP, et al. (2009). Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann. Oncol. 20: 736-740.
http://dx.doi.org/10.1093/annonc/mdn698
PMid:19223573
Miyake H, Hara I, Kamidono S and Eto H (2004). Oxidative DNA damage in patients with prostate cancer and its response to treatment. J. Urol. 171: 1533-1536.
http://dx.doi.org/10.1097/01.ju.0000116617.32728.ca
PMid:15017214
Mo Z, Gao Y, Cao Y, Gao F, et al. (2009). An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 69: 662-688.
http://dx.doi.org/10.1002/pros.20907
PMid:19143011
Nakazato H, Suzuki K, Matsui H, Koike H, et al. (2003). Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res. 23: 2897-2902.
PMid:12926131
Ntais C, Polycarpou A and Ioannidis JP (2005). Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 14: 176-181.
PMid:15668493
Rebbeck TR (1997). Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6: 733-743.
PMid:9298582
Ryberg D, Skaug V, Hewer A, Phillips DH, et al. (1997). Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18: 1285-1289.
http://dx.doi.org/10.1093/carcin/18.7.1285
PMid:9230269
Shepard TF, Platz EA, Kantoff PW, Nelson WG, et al. (2000). No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. Cancer Epidemiol. Biomarkers Prev. 9: 1267-1268.
PMid:11097238
Sikka SC (2003). Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention - a mechanistic approach. Curr. Med. Chem. 10: 2679-2692.
http://dx.doi.org/10.2174/0929867033456341
PMid:14529458
Sreeja L, Syamala V, Hariharan S, Syamala VS, et al. (2008). Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J. Exp. Ther. Oncol. 7: 73-85.
PMid:18472644
Srivastava DS, Mandhani A, Mittal B and Mittal RD (2005). Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int. 95: 170-173.
http://dx.doi.org/10.1111/j.1464-410X.2005.05271.x
PMid:15638917
Steinhoff C, Franke KH, Golka K, Thier R, et al. (2000). Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch. Toxicol. 74: 521-526.
http://dx.doi.org/10.1007/s002040000161
PMid:11131031
Vijayalakshmi K, Vettriselvi V, Krishnan M, Shroff S, et al. (2005). Polymorphisms at GSTM1 and GSTP1 gene loci and risk of prostate cancer in a South Indian population. Asian Pac. J. Cancer Prev. 6: 309-314.
PMid:16235991
Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, et al. (1999). Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 9: 333-340.
http://dx.doi.org/10.1097/00008571-199906000-00008
PMid:10471065
Waris G and Ahsan H (2006). Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog. 5: 14.
http://dx.doi.org/10.1186/1477-3163-5-14
PMid:16689993 PMCid:1479806
Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, et al. (1994). Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224: 893-899.
http://dx.doi.org/10.1111/j.1432-1033.1994.00893.x
PMid:7925413
“Risk of colorectal cancer associated with the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the Kashmiri population”, vol. 10, pp. 1200-1210, 2011.
, Bagley PJ and Selhub J (1998). A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. U. S. A. 95: 13217-13220.
doi:10.1073/pnas.95.22.13217
Bailey LB and Gregory JF III (1999). Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J. Nutr. 129: 919-922.
PMid:10222379
Center MM, Jemal A and Ward E (2009a). International trends in colorectal cancer incidence rates. Cancer Epidemiol. Biomark. Prev. 18: 1688-1694.
doi:10.1158/1055-9965.EPI-09-0090
Center MM, Jemal A, Smith RA and Ward E (2009b). Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59: 366-378.
doi:10.3322/caac.20038
PMid:19897840
Chandy S, Sadananda Adiga MN, Ramachandra N, Krishnamoorthy S, et al. (2010). Association of methylenetetrahydrofolate reductase gene polymorphisms & colorectal cancer in India. Indian J. Med. Res. 131: 659-664.
PMid:20516537
Chen J, Giovannucci E, Kelsey K, Rimm EB, et al. (1996). A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 56: 4862-4864.
PMid:8895734
Chen J, Giovannucci E, Hankinson SE, Ma J, et al. (1998). A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 19: 2129-2132.
doi:10.1093/carcin/19.12.2129
PMid:9886567
Cicek MS, Nock NL, Li L, Conti DV, et al. (2004). Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomark. Prev. 13: 1331-1336.
PMid:15298954
Frosst P, Blom HJ, Milos R, Goyette P, et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10: 111-113.
doi:10.1038/ng0595-111
PMid:7647779
Haghighi MM, Radpour R, Mahmoudi T, Mohebbi SR, et al. (2009). Association between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. Oncol. Res. 18: 57-63.
doi:10.3727/096504009789954636
Houlston RS and Tomlinson IP (2001). Polymorphisms and colorectal tumor risk. Gastroenterology 121: 282-301.
doi:10.1053/gast.2001.26265
PMid:11487538
Jemal A, Bray F, Center MM, Ferlay J, et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61: 69-90.
doi:10.3322/caac.20107
PMid:21296855
Keku T, Millikan R, Worley K, Winkel S, et al. (2002). 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol. Biomark. Prev. 11: 1611- 1621.
PMid:12496052
Kono S and Chen K (2005). Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci. 96: 535-542.
doi:10.1111/j.1349-7006.2005.00090.x
PMid:16128738
Levine AJ, Siegmund KD, Ervin CM, Diep A, et al. (2000). The methylenetetrahydrofolate reductase 677C→T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol. Biomark. Prev. 9: 657-663.
PMid:10919734
Lucock M (2000). Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol. Genet. Metab. 71: 121-138.
doi:10.1006/mgme.2000.3027
PMid:11001804
Ma J, Stampfer MJ, Giovannucci E, Artigas C, et al. (1997). Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 57: 1098-1102.
PMid:9067278
Marugame T, Tsuji E, Kiyohara C, Eguchi H, et al. (2003). Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int. J. Epidemiol. 32: 64-66.
doi:10.1093/ije/dyg004
PMid:12690011
Mir MM, Dar NA, Gochhait S, Zargar SA, et al. (2005). p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int. J. Cancer 116: 62-68.
doi:10.1002/ijc.21002
PMid:15761872
Murtaza I, Mushtaq D, Margoob MA, Dutt A, et al. (2006). A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir Valley. World J. Gastroenterol. 12: 4033-4037.
PMid:16810754
Park KS, Mok JW and Kim JC (1999). The 677C > T mutation in 5,10-methylenetetrahydrofolate reductase and colorectal cancer risk. Genet. Test. 3: 233-236.
doi:10.1089/gte.1999.3.233
PMid:10464674
Sachse C, Smith G, Wilkie MJ, Barrett JH, et al. (2002). A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839-1849.
doi:10.1093/carcin/23.11.1839
PMid:12419832
Saffroy R, Lemoine A and Debuire B (2005). MTHFR (5,10-Methylenetetrahydrofolate reductase) Atlas Genet Cytogenet Oncol Haematol. Available at [http://AtlasGeneticsOncology.org/Genes/MTHFRID41448ch1p36.html]. Accessed 2009.
Salam I, Hussain S, Mir MM, Dar NA, et al. (2009). Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir Valley: a high-risk area. Mol. Cell Biochem. 332: 51-58.
doi:10.1007/s11010-009-0173-7
PMid:19513816
Sameer AS, Chowdri NA, Syeed N, Banday MZ, et al. (2010a). SMAD4 - molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer 10: 300.
doi:10.1186/1471-2407-10-300
PMid:20565773 PMCid:2927996
Sameer AS, Shah ZA, Syeed N, Banday MZ, et al. (2010b). TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet. Mol. Res. 9: 651-660.
doi:10.4238/vol9-2gmr751
PMid:20449797
Shannon B, Gnanasampanthan S, Beilby J and Iacopetta B (2002). A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 50: 520-524.
doi:10.1136/gut.50.4.520
PMid:11889073 PMCid:1773174
Siddiqi M, Kumar R, Fazili Z, Spiegelhalder B, et al. (1992). Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India). Carcinogenesis 13: 1331-1335.
doi:10.1093/carcin/13.8.1331
PMid:1499084
Slattery ML, Potter JD, Samowitz W, Schaffer D, et al. (1999). Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol. Biomark. Prev. 8: 513-518.
PMid:10385141
Ulrich CM, Kampman E, Bigler J, Schwartz SM, et al. (1999). Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol. Biomark. Prev. 8: 659-668.
PMid:10744125
Wagner C (1995). Biochemical Role of Folate in Cellular Metabolism. In: Folate in Health and Disease (Bailey LB, ed.) Marcel Dekker, New York, 23-42.
Yin G, Kono S, Toyomura K, Hagiwara T, et al. (2004). Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci. 95: 908-913.
doi:10.1111/j.1349-7006.2004.tb02201.x
PMid:15546509
“TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population”, vol. 9, pp. 651-660, 2010.
, Beckman G, Birgander R, Sjalander A, Saha N, et al. (1994). Is p53 polymorphism maintained by natural selection? Hum. Hered. 44: 266-270.
http://dx.doi.org/10.1159/000154228
PMid:7927355
Bojesen SE and Nordestgaard BG (2008). The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7: 158-163.
http://dx.doi.org/10.4161/cc.7.2.5249
PMid:18256523
Boyle P and Leon ME (2002). Epidemiology of colorectal cancer. Br. Med. Bull. 64: 1-25.
http://dx.doi.org/10.1093/bmb/64.1.1
PMid:12421722
Costa S, Pinto D, Pereira D, Rodrigues H, et al. (2008). Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8: 32.
http://dx.doi.org/10.1186/1471-2407-8-32
PMid:18230179 PMCid:2254432
Devesa SS and Chow WH (1993). Variation in colorectal cancer incidence in the United States by subsite of origin. Cancer 71: 3819-3826.
http://dx.doi.org/10.1002/1097-0142(19930615)71:12<3819::AID-CNCR2820711206>3.0.CO;2-L
Dumont P, Leu JI, Della Pietra AC, George DL, et al. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365.
http://dx.doi.org/10.1038/ng1093
PMid:12567188
Felley-Bosco E, Weston A, Cawley HM, Bennett WP, et al. (1993). Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am. J. Hum. Genet. 53: 752-759.
PMid:8352280 PMCid:1682404
Gapstur SM, Potter JD and Folsom AR (1994). Alcohol consumption and colon and rectal cancer in postmenopausal women. Int. J. Epidemiol. 23: 50-57.
http://dx.doi.org/10.1093/ije/23.1.50
PMid:8194924
Gemignani F, Moreno V, Landi S, Moullan N, et al. (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23: 1954-1956.
http://dx.doi.org/10.1038/sj.onc.1207305
PMid:14647431
Hamajima N, Matsuo K, Suzuki T, Nakamura T, et al. (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett. 181: 81-85.
http://dx.doi.org/10.1016/S0304-3835(02)00041-1
Hiyama T, Tanaka S, Kitadai Y, Ito M, et al. (2002). p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int. J. Cancer 100: 304-308.
http://dx.doi.org/10.1002/ijc.10483
PMid:12115545
Iacopetta B (2003). TP53 mutation in colorectal cancer. Hum. Mutat. 21: 271-276.
http://dx.doi.org/10.1002/humu.10175
PMid:12619112
Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, et al. (2006). The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol. Rep. 16: 65-71.
PMid:16786124
Irarrazabal CE, Rojas C, Aracena R, Marquez C, et al. (2003). Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett. 144: 69-76.
http://dx.doi.org/10.1016/S0378-4274(02)00336-3
Katkoori VR, Jia X, Shanmugam C, Wan W, et al. (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin. Cancer Res. 15: 2406-2416.
http://dx.doi.org/10.1158/1078-0432.CCR-08-1719
PMid:19339276 PMCid:3635077
Lee JM, Lee YC, Yang SY, Shi WL, et al. (2000). Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer 89: 458-464.
http://dx.doi.org/10.1002/1097-0215(20000920)89:5<458::AID-IJC10>3.0.CO;2-R
Leu JI, Dumont P, Hafey M, Murphy ME, et al. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak- Mcl1 complex. Nat. Cell Biol. 6: 443-450.
http://dx.doi.org/10.1038/ncb1123
PMid:15077116
Li X, Dumont P, Della PA, Shetler C, et al. (2005). The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 280: 24245-24251.
http://dx.doi.org/10.1074/jbc.M414637200
PMid:15851479
Lung FW, Lee TM, Shu BC and Chang FH (2004). p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J. Cancer Res. Clin. Oncol. 130: 728-732.
http://dx.doi.org/10.1007/s00432-004-0605-4
PMid:15365822
Marin MC, Jost CA, Brooks LA, Irwin MS, et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25: 47-54.
http://dx.doi.org/10.1038/75586
PMid:10802655
Mir MM, Dar NA, Gochhait S, Zargar SA, et al. (2005). p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int. J. Cancer 116: 62-68.
http://dx.doi.org/10.1002/ijc.21002
PMid:15761872
Murphy ME (2006). Polymorphic variants in the p53 pathway. Cell Death Differ. 13: 916-920.
http://dx.doi.org/10.1038/sj.cdd.4401907
PMid:16557270
Murtaza I, Mushtaq D, Margoob MA, Dutt A, et al. (2006). A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley. World J. Gastroenterol. 12: 4033-4037.
PMid:16810754
Perez LO, Abba MC, Dulout FN and Golijow CD (2006). Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J. Gastroenterol. 12: 1426-1429.
PMid:16552814
Pietsch EC, Humbey O and Murphy ME (2006). Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
http://dx.doi.org/10.1038/sj.onc.1209367
PMid:16550160
Pinto GR, Yoshioka FK, Silva RL, Clara CA, et al. (2008). Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 7: 207-216.
http://dx.doi.org/10.4238/vol7-1gmr415
PMid:18393224
Sameer AS, Ul Rehman S, Pandith AA, Syeed N, et al. (2009). Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J. Gastroenterol. 15: 244-252.
http://dx.doi.org/10.4103/1319-3767.56102
PMid:19794270 PMCid:2981841
Sayhan N, Yazici H, Budak M, Bitisik O, et al. (2001). P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res. Commun. Mol. Pathol. Pharmacol. 109: 25-34.
PMid:11458982
Schneider-Stock R, Boltze C, Peters B, Szibor R, et al. (2004). Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6: 529-535.
http://dx.doi.org/10.1593/neo.04178
PMid:15548361 PMCid:1531656
Shah A and Jan GM (1990). Pattern of cancer at Srinagar (Kashmir). Indian J. Pathol. Microbiol. 33: 118-123.
PMid:2391141
Siddiqi M, Kumar R, Fazili Z, Spiegelhalder B, et al. (1992). Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India). Carcinogenesis 13: 1331-1335.
http://dx.doi.org/10.1093/carcin/13.8.1331
PMid:1499084
Sjalander A, Birgander R, Athlin L, Stenling R, et al. (1995). P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16: 1461-1464.
http://dx.doi.org/10.1093/carcin/16.7.1461
PMid:7614678
Sjalander A, Birgander R, Hallmans G, Cajander S, et al. (1996). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316.
http://dx.doi.org/10.1093/carcin/17.6.1313
PMid:8681448
Soussi T and May P (1996). Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260: 623-637.
http://dx.doi.org/10.1006/jmbi.1996.0425
PMid:8709143
Thomas M, Kalita A, Labrecque S, Pim D, et al. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell Biol. 19: 1092-1100.
PMid:9891044 PMCid:116039
Toyama T, Zhang Z, Nishio M, Hamaguchi M, et al. (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9: R34.
http://dx.doi.org/10.1186/bcr1682
PMid:17537232 PMCid:1929098
Whibley C, Pharoah PD and Hollstein M (2009). p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9: 95-107.
http://dx.doi.org/10.1038/nrc2584
PMid:19165225
Zehbe I, Voglino G, Delius H, Wilander E, et al. (1998). Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352: 1441-1442.
http://dx.doi.org/10.1016/S0140-6736(05)61263-9
Zhu ZZ, Wang AZ, Jia HR, Jin XX, et al. (2007). Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn. J. Clin. Oncol. 37: 385-390.
http://dx.doi.org/10.1093/jjco/hym034
PMid:17599946
Zhu ZZ, Liu B, Wang AZ, Jia HR, et al. (2008). Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J. Zhejiang. Univ. Sci. B 9: 847-852.
http://dx.doi.org/10.1631/jzus.B0820100
PMid:18988302 PMCid:2579946